Corona Remedies IPO Opens: Key Details & Strong GMP
Corona Remedies IPO subscription starts Dec 8. Price band ₹1008-1062, aims to raise ₹655 cr. Grey market premium signals strong investor interest. Details inside.
Category : Search result: pharma stock
Corona Remedies IPO Subscription Begins, GMP at ₹290
Corona Remedies' ₹655 crore IPO opens today. With a price band of ₹1,008-₹1,062 and a strong GMP, analysts give a 'Subscribe for long term' rating. Key dates and details inside.
Odisha Approves Pharma & Medtech Policy 2025
Odisha's new Pharma & Medtech Policy 2025 aims to make the state a strategic hub for healthcare manufacturing. The policy includes plans for dedicated industrial parks and a roadmap aligned with India's 2047 vision. Read more.
Himachal Pharma Sector Faces Major Trust Crisis
Himachal Pradesh's pharmaceutical hub is in turmoil as 38 firms lose WHO-GMP certification, raising serious quality concerns. Discover the causes and impact.
Nivin Pauly's 'Pharma' Trailer Targets Unethical Drug Practices
Nivin Pauly's OTT debut 'Pharma' trailer reveals a medical rep exposing dangerous drugs. The series premieres on JioCinema December 19 in 7 languages. Read more.
Laurus Labs aims for 50% revenue from CDMO business in 5 years
Hyderabad's Laurus Labs plans aggressive CDMO growth, targeting 50% of revenue in five years. CEO Dr. Satyanarayana Chava reveals strategy focusing on cell & gene therapy and global expansion. Read more.
Granules India's US facility passes FDA GMP inspection
Granules India's US subsidiary, Granules Consumer Health LLC, successfully cleared a USFDA GMP inspection with zero observations. This marks a significant achievement for the Hyderabad-based pharma major's OTC product operations in America.
Corona Remedies IPO: Key Dates, Price Band, Details
Corona Remedies IPO opens Dec 8, 2025, to raise ₹655.37 crore. Check price band, GMP, financials, and key dates for this pharma company's public issue.
Market Opens Strong: Nifty Above 25,400, Gift Nifty Up
Indian stock markets opened strong on December 3, 2025, with Nifty crossing 25,400. Key stocks like TCS and Sun Pharma in focus. Read for full analysis and trading cues.
Wockhardt Shares Jump 6% on USFDA NDA Acceptance for Zaynich
Wockhardt's share price surged over 6% after the USFDA accepted its New Drug Application for Zaynich, a novel antibiotic. Discover the details and market impact.
Sun Pharma's Ilumya for Psoriasis Launched in India
Sun Pharma introduces its global biologic Ilumya for moderate-to-severe plaque psoriasis in India. Backed by Phase-3 data, it offers long-lasting clearance with a strong safety profile. Learn more about this targeted therapy.
India's Bulk Drug Makers Ramp Up CDMO Investments
Indian API manufacturers are shifting to high-value contract development, targeting $22-25 billion market by 2035 as global pharma diversifies from China. Read about the growth trajectory.
Pharma Chemical Firms Outperform with 7% Growth
Speciality chemical makers supplying pharma CDMOs post 7% sales growth, outpacing non-pharma peers. Strong margins and global shifts fuel this resilient sector. Read more.
November 2025 IPO Analysis: Market Trends Revealed
November 2025 witnessed 9 IPOs with 12 listings. Groww leads with 58.85% gains while experts warn of investor fatigue and unrealistic valuations. Read full analysis.
Sudeep Pharma Shares Jump 33% After Strong IPO Listing
Sudeep Pharma shares surged 33.78% in market debut, exceeding expectations. Analysts advise partial profit booking while maintaining long-term optimism. Read expert views on buy/sell strategy.
Sudeep Pharma IPO Lists at 23% Premium on NSE, BSE
Sudeep Pharma shares surged 23% in stock market debut today, outperforming grey market expectations. The ₹895-crore IPO was subscribed 93.71 times. Read full analysis.
Sudeep Pharma IPO Lists on BSE, NSE Today
Sudeep Pharma makes its stock market debut today. With a GMP of ₹121, the IPO is set for 20% listing gains after a blockbuster 93.72 times subscription. Get all the live details.
Sudeep Pharma IPO Lists Today with Strong Grey Market Premium
Sudeep Pharma shares list on BSE and NSE today after 93.72 times subscription. Grey market signals 20% premium debut. Full details on pricing and investor response.
Sudeep Pharma IPO Listing on Nov 28 with Strong GMP
Sudeep Pharma IPO makes Dalal Street debut on November 28. Grey market premium hits ₹100, signaling 15% listing gain. Discover subscription details and key facts.
Bokaro Pharma Owner Faces NDPS Case for Codeine Trade
Bokaro police register FIR against Aryan Singh of New Sun Pharma for illegal codeine syrup trade. 32,000 bottles seized. Read the full investigation details.
Indian Companies Set for Semaglutide Device Windfall
Shaily Engineering and Gland Pharma positioned to benefit from India's semaglutide gold rush as patent expiry opens market for generic weight-loss drugs. Discover how these companies are preparing.
Sudeep Pharma IPO Allotment Status Today
Sudeep Pharma IPO allotment finalized today after massive 93.71x subscription. GMP at ₹87 signals 14.67% listing gain. Track your allotment status now!
Sudeep Pharma IPO Allotment Today: Check Status Now
Sudeep Pharma IPO allotment likely on November 26. Learn how to check allotment status via BSE, NSE, registrar. Strong 93.72x subscription signals investor confidence.
Sudeep Pharma IPO Subscribed 94 Times
Sudeep Pharma's ₹895 crore IPO witnessed massive demand, subscribed 94 times. QIB portion booked 213x. Shares may list at a 14% premium. Key details inside.
Sudeep Pharma IPO Subscribed 5.09x, Closes Nov 25
Sudeep Pharma IPO sees massive 5.09x subscription on Day 2. Grey market premium hits ₹86. Allotment scheduled for November 26. Apply before closing tomorrow!
Lupin: Undervalued Pharma Giant at 21x P/E?
Lupin stocks trade at 21.7x P/E despite record earnings and 80 new products pipeline. Discover why this pharma giant might be undervalued and poised for next growth cycle with biosimilars and complex generics.
Sudeep Pharma IPO Day 2: GMP Signals Strong Gains
Sudeep Pharma's ₹895 crore IPO is fully subscribed. With a GMP of ₹121, investors eye a 20% listing gain. Track all live updates here.
Sudeep Pharma IPO Fully Subscribed on Day 1
Sudeep Pharma's IPO concludes November 25 after strong第一天 response. Grey market premium hits ₹121, signaling 20% listing gains. Key dates and subscription details revealed.
Aurobindo Pharma China Facility Targets Break-Even by FY26
Aurobindo Pharma's China facility currently faces $1M loss but aims for break-even by Q3-Q4 FY26. CFO outlines growth drivers including Pen-G ramp-up and biosimilar commercialization.
Karnataka Health Minister's Directive to Pharma Industry
Karnataka Health Minister Dinesh Gundu Rao urges the pharma sector to adhere to regulations, highlighting critical public health and industry credibility issues.
Page 1 of 4